JP5619484B2 - Composition for suppressing urine odor production - Google Patents

Description

  The present invention relates to a composition for suppressing urine odor production comprising a β-glucuronidase inhibitor and 0.01 to 10% by weight of an alkylglycoside type nonionic surfactant.

  In recent years, it has been strongly desired to remove not only the appearance of dirt but also the odor reminiscent of the presence of dirt due to the increase in consumer hygiene. Especially for urine and feces, the existence cannot be separated from the living environment. Furthermore, since the odor strongly reminds the excrement itself, discomfort given to humans is particularly great among the bad odors of the living environment. In toilets, stool can be easily discharged outdoors by washing with water, but a small amount of urine remains as a splash on the toilet periphery, toilet floor, inner wall, etc., and its presence is difficult to check visually. Remains on the spot for a long time and tends to be a source of bad odor. In addition, sanitary products such as underwear, diapers, and sanitary products may exist in the living environment for a certain period of time with urine attached, and can be a source of malodor originating from urine.

  On the other hand, the odor of urine immediately after urination is very weak, and it is considered that most of the malodorous components derived from urine are generated with the passage of time due to the action of metabolic enzymes derived from microorganisms. For this reason, development of the technique which can suppress continuously the production | generation of the malodorous component from urine from the beginning is desired.

  Such urine-derived malodorous components include ammonia produced from urea by urease, and as its production suppression technology, ammonia generation suppression technology using a urease activity inhibitor has been proposed (for example, Patent Documents 1 to 3). 4).

  However, because ammonia has a high threshold as a bad odor component (it does not feel odor unless it is high in concentration), nowadays the excrement is immediately discharged to the outdoors due to the widespread use of the flushing method. Scenes that feel strong are very rare.

  Patent Document 5 proposes a technique for suppressing the generation of urine odor using a β-glucuronidase inhibitor, assuming that phenolic compounds and indoles metabolized from urine by β-glucuronidase derived from microorganisms greatly contribute to urine odor. ing.

JP 2006-255290 A JP 2004-91338 A Japanese Patent Laid-Open No. 5-137774 JP 2006-192127 A International Publication No. 2009/037861 Pamphlet

  The technique of Patent Document 5 is considered to be particularly effective when β-glucuronidase derived from microorganisms is released outside the cell. However, it is thought that β-glucuronidase is present not only extracellularly but also in cells and in areas where the agent is difficult to act from the outside, such as the periplasmic space in gram-negative bacteria. There is no known effective technique for β-glucuronidase retained by the cell structure (hereinafter referred to as “intracellular β-glucuronidase”). In particular, when the cell membrane of a microorganism is not destroyed, for example, when a bactericidal agent is not included, it is considered extremely difficult to make a β-glucuronidase inhibitor act effectively on intracellular β-glucuronidase.

  That is, the problem of the present invention is derived from urine by effectively inhibiting β-glucuronidase activity not only against β-glucuronidase dissolved or dispersed in urine but also against intracellular β-glucuronidase of microorganisms. It is providing the composition which can suppress the production | generation of a bad odor effectively.

  We have surprisingly found that certain surfactants do not exert a bactericidal effect, i.e. at concentrations that do not disrupt the cell membrane, but surprisingly, in combination with β-glucuronidase inhibitors, -We have found that the effect of β-glucuronidase inhibitors on glucuronidase is improved. In addition, a composition comprising a β-glucuronidase inhibitor and a specific surfactant continuously suppresses the generation of unpleasant urine odor, and the composition is used in products related to urine. It was found that a urine odor production inhibitory effect can be imparted to the above.

  That is, the present invention provides a composition for suppressing urine odor production comprising a β-glucuronidase inhibitor and 0.01 to 10% by weight of an alkylglycoside nonionic surfactant.

  Furthermore, this invention provides the discharge type product which accommodates the said composition for urine odor production | generation suppression in the container provided with a discharge device.

  Furthermore, the present invention provides a method for suppressing the generation of urine odor, wherein the composition for suppressing urine odor generation is applied before urine adheres to an object or before drying after urine has adhered.

  The composition for suppressing urine odor production of the present invention can continuously suppress the odor generated from the urine over time.

It is a figure which shows the influence on the osmosis | permeation amount or adhesion amount of the beta-glucuronidase inhibitor with respect to a microbial cell by using together surfactant.

  The composition for suppressing urine odor production according to the present invention is effective not only for β-glucuronidase dissolved or dispersed in urine but also for microorganisms, particularly intracellular β-glucuronidase of urine odor producing bacteria. Suppressing the odor generated with the passage of time from the attached urine for any articles or parts that may be attached to the toilet environment, sanitary products, clothing such as underwear, skin, or bedding To suppress. For this reason, the composition for suppressing urine odor production of the present invention has excellent deodorizing effects, environmental hygiene products such as detergents and deodorants, and animals such as diapers, sanitary products, dog excrement sheets such as dogs and cats. It is useful in sanitary products such as excrement related products.

  In the above, urine odor producing bacteria are those having β-glucuronidase activity among microorganisms that inhabit urine or the environment related to urine, urine of animals such as humans, feces, or a mixture of urine and feces, Preferably, urine, stool, or a mixture of urine and stool attached to a toilet environment such as a toilet bowl or toilet floor or a sanitary product, or a toilet environment such as a toilet bowl or toilet floor having a history of adhesion or contact thereof It is a β-glucuronidase active bacterium extracted from the inside or sanitary products, and examples thereof include Staphylococcus bacteria and Escherichia coli.

  Further, in the present invention, intracellular β-glucuronidase is defined as β-glucuronidase existing in the periplasmic space or the like in cells, cell membranes or gram-negative bacteria, and retained in such a cell structure, and present in the cytoplasm. -Not limited to glucuronidase. In the present invention, the intracellular β-glucuronidase of the urine odor producing bacteria was cultured, for example, under the conditions in which β-glucuronidase was expressed, and β-glucuronidase dissolved or dispersed in the culture supernatant was removed by centrifugation. The cell part can be preferably used.

  Further, since the composition for suppressing urine odor production of the present invention effectively suppresses β-glucuronidase activity, it is also a means for solving various problems other than urine odor caused by the action of β-glucuronidase. For example, it can be used as a body odor production inhibitor derived from volatile steroids, a drug or food that reduces the occurrence of bladder cancer or colon cancer.

[Β-glucuronidase inhibitor]
β-glucuronidase is an enzyme that hydrolyzes glucuronide-conjugated compounds (glucuronides) with various alcohols, phenols, amines, etc., and exists in many organisms such as bacteria, fungi, plants, and animals. It has been known. In the present invention, β-glucuronidase derived from bacteria and fungi is important because microorganisms are greatly involved in the degradation of urine excreted outside the body. The microorganisms are known to have β- glucuronidase, for example Escherichia coli, Lactobacillus brevis, Propionibacterium acnes , Clostridium perfringens, Staphylococcus haemolyticus, Streptococcus agalactiae, Streptococcus pyogenes, Haemophilus somunus, Shigela sonnei, Aspergillus niger , and these microorganisms All β-glucuronidases derived from are classified into enzyme groups having a common domain. Furthermore, β-glucuronidase derived from human plasma is also classified into a similar protein group.

  That is, in the present invention, the β-glucuronidase inhibitor is a substance that suppresses the hydrolysis reaction of glucuronide by acting on β-glucuronidase, and exhibits an inhibitory effect in a test using β-glucuronidase derived from bacteria or fungi. In particular, those showing an inhibitory effect in a test using β-glucuronidase derived from E. coli are more preferred.

  Hereinafter, such β-glucuronidase inhibitors are listed, but the β-glucuronidase inhibitors used in the present invention are not limited to those described below as long as they have the above-described action. .

1. Macrocyclic ketone represented by the following general formula (1).

Wherein, n ₁ represents an integer of 9 to 13, m ₁ represents an integer of 0 to 2, may contain one double bond broken line. ]

  For example, 3-methyl-4 (5) -cyclopentadecene-1-one (Firmenich product name; Musenon Delta), 3-methylcyclopentadecanone (Firmenich product name; Muscon), 4-cyclopentadecene-1 -On (Firmenich product name; Egizartenon, IFF product name: Musk Z-4), 5-cyclohexadecen-1-one (Manda Scent Inc. product name: Musk TM2), 8-cyclohexadecen-1-one (Symrise) Company product name: Globanon), 9-cycloheptadecen-1-one (Firmenich product name: Civeton), cyclopentadecanone (Firmenich product name: Exalton).

Among the macrocyclic ketone compounds represented by the general formula (1), those containing one double bond in the cyclic structure are preferable, for example, 3-methyl-4 (5) -cyclopentadecene-1-one, 4-cyclopentadecene-1-one, 5-cyclohexadecene-1-one, 8-cyclohexadecene-1-one, and 9-cycloheptadecene-1-one. Furthermore, the double bond is preferably present in the carbon-carbon bond located farthest from the carbonyl group of the ketone, or adjacent to the carbon-carbon bond, such as 8-cyclohexadecen-1-one, 9-cycloheptadecen-1-one. In the general formula (1), n ₁ + m ₁ is preferably 9 to 13, and n ₁ is preferably 11 or 12.

2. Macrocyclic lactone represented by the following general formula (2).

Wherein, n ₂ represents an integer of 9 to 13, m ₂ represents an integer of 0 to 3, including one double bond broken line. However, it is assumed that satisfies n ₂ + m ₂ = 9~14. ]

Examples thereof include 4 (5) -cyclopentadecenolide (Firmenich product name: havanolide) and 7-cyclohexadecenolide (ambretride). In the macrocyclic lactone compound represented by the general formula (2), those in which n ₂ is 12 are preferable, and 7-cyclohexadecenolide is particularly preferable.

3. Macrocyclic oxalactone represented by the following general formula (3).

[In formula, R shows a hydrogen atom or a C1-C3 alkyl group, p shows the integer of 6-11, q shows the integer of 2-6. However, p + q = 10-14 shall be satisfy | filled. ]

  For example, 10-oxa-16-hexadecanolide (product name of Takasago International Corporation; oxalide), 11-oxa-16-hexadecanolide (product name of Quest; musk R1), 12-oxa-16-hexadecane Decanoride (Quest product name: Serboride). In the macrocyclic oxalactone compound represented by the general formula (3), those having p + q of 13 are preferable, and 10-oxa-16-hexadecanolide is particularly preferable.

4). Ketones listed below.
Cyclopentadecanone (Firmenich product name; Exalton), 3-methylcyclopentadecanone (Firmenich product name; Muscon), 3-methyl-4 (5) -cyclopentadecen-1-one (Firmenich product name) ; Musenon Delta), 4-cyclopentadecen-1-one (Firmenich product name; Egizartenon, IFF product name: Musk Z-4), 5-cyclohexadecene-1-one (Iwata Inc. product name; Musk TM2) , 8-cyclohexadecen-1-one (Symrise product name: Globanone), 9-cycloheptadecen-1-one (Firmenich product name: Sibeton), 2-pentylcyclopentenone, α-damascone, β-damascone , Cis-jasmon, 2-heptylcyclopentanone, α-ionone, β-ionone, α-methylionone, γ-methylionone, 7-methyl-3,4-dihydro- (2H) -1,5-benzodioxepin -3-On (Danisco product name: Caro Nootkaton, 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-acetonaphthone (IFF product name: ISOE Super).

5. Esters listed below.
4 (5) -cyclopentadecenolide (Firmenich product name: havanolide), 7-cyclohexadecenolide (ambretride), 10-oxa-16-hexadecanolide (product name of Takasago International Corporation; Oxalide) ), 11-oxa-16-hexadecanolide (Quest product name: Musk R1), citronellyl acetate, linalyl acetate, terpinyl acetate, cinnamyl acetate, cis-3-hexenylbenzoate, methyl-2-noninoate (Common name: methyl octane carbonate).

6). Aldehydes listed below.
Anisaldehyde, synamic aldehyde, cumin aldehyde, cyclamenaldehyde, ethyl vanillin, 2-methyl-3- (3,4-methylenedioxyphenyl) -propanal (IFF product name: helional), 2-methyl-3- (4-tert-Butylphenyl) -propanal (Givaudan product name; Liliar), phenylacetaldehyde, 3-phenylpropanal, vanillin, 4- (tricyclo [5.2.1.0 ^2,6 ] decylidene-8) butenal (IFF Company name: Dupicar), dimethyl tetrahydrobenzaldehyde (IFF company name: tripral, Quest product name: Ligstral), 4- (4-hydroxy-4-methylpentyl) -3-cyclohexene-1-carboxaldehyde (IFF company) (Product name: Lyral), 4- (4-Methyl-3-pentenyl) -3-cyclohexene-1-carboxaldehyde (Product name: Mylac Aldehi) ), 2,6-nonadienal, 2-methyl undecanal, hydroxy citronellal, citral.

7). Alcohols listed below.
Citronellol, geraniol, nerol, linalool, linalool oxide, terpineol, cinnamic alcohol, eugenol, 3-methyl-5-phenyl-1-pentanol (Firmenich product name; phenylhexanol), vetiverol.

8). Ethers listed below.
Estragole, 6,6,9α-trimethyl-3α-ethyldodecahydronaphtho [2,1-b] furan (IFF product name: glycalva), p-cresyl methyl ether, phenylethyl isoamyl ether, 1-methoxycyclo Dodecane (Symrise product name; Paris Sandin), 1-methyl-1-methoxycyclododecane (Givaudan product name; Madrox), 4,8,12-trimethyl-13-oxabicyclo [10.1.0] trideca-4 , 8-Diene (Firmenich product name: Cedroxide).

9. Terpenes listed below.
α-Ferlandolene, citronellylnitrile.

  As the β-glucuronidase inhibitor, those isolated from animals and plants may be used, or those chemically synthesized may be used. In addition, plant extracts such as essential oils containing these compounds, for example, vetiver oil, basil oil, clove oil, cinnamon oil, grapefruit oil and the like may be used as they are as β-glucuronidase inhibitors.

  In addition, D-glucaro-1,4-lactone, which is a lactone compound derived from glucuronic acid, and D-glucaro-1,4-lactone analogs such as acegraton, D-glucuronic acid, and D-galacturonic acid; lysophosphatidine Lysophospholipids such as acid, lysophosphatidylcholine, lysophosphatidylethanolamine, and lysophosphatidylglycerol; natural glucuronide type inhibitors found from herbal ingredients such as baicalin; and protein adsorbents such as tannins and cationic polymers It can be used as a β-glucuronidase inhibitor.

  Furthermore, plants or fungi such as urgon, gobishi, clove, gardenia, sicon, peonies, entomons, chamomiles, camellia, comfrey, flax, licorice, embers, cordyceps, chimpi, nettle, hamamelis, akebi, etc. It can be used as a β-glucuronidase inhibitor of the invention.

  The above plants and fungi can be used as is or after pulverizing one or more of the whole plant, leaves, roots, rhizomes, fruits, seeds and flowers, and fungi of the plants. When it is set as an extract, it can obtain by solvent-extracting the said plant or fungi, or its ground material at normal temperature or a heating. In the extraction, an extraction device such as a Soxhlet extractor can be used.

  Solvents used for extraction are water; alcohols such as methanol, ethanol and propanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; tetrahydrofuran and dimethyl ether Linear and cyclic ethers such as dichloromethane; hydrogen halides such as dichloromethane, chloroform and carbon tetrachloride; hydrocarbons such as hexane, cyclohexane and petroleum ether; aromatic hydrocarbons such as benzene and toluene; Polyethers; pyridines and the like can be mentioned, and these can be used alone or as a mixture. A supercritical fluid such as carbon dioxide can also be used.

  The obtained various solvent extracts can be used as they are, and can also be used as a diluted solution or concentrated solution, or after being concentrated or lyophilized, in the form of powder or paste. Moreover, it is also possible to remove inactive impurities from the extract by a technique such as liquid-liquid distribution, and it is preferable to use such a material in the present invention. These may be used after performing treatments such as deodorization and decolorization by a known method, if necessary.

Furthermore, in the present invention, it is more preferable to select and use a β-glucuronidase inhibitor having a high inhibitory activity per weight. Specifically, 0.1% by weight of the inhibitor in the reaction solution was subjected to hydrolysis reaction of p-nitrophenyl-β-D-glucuronide (PNPG) with 1.6 units / mL β-glucuronidase Type VII-A derived from E. coli (400 nm It is preferable to suppress 60% or more (which can be quantified by measuring absorbance), and more preferable to suppress the above reaction by 80% or more even when the amount is 0.01% by weight during the reaction. Examples of such inhibitors include macrocyclic compounds represented by any one of the general formulas (1) to (3), and these can be suitably used. Further, a macrocyclic ketone represented by the general formula (1) is preferable, and among these, 8-cyclohexadecene-1-one and 9-cycloheptadecen-1-one are more preferable. Hexadecen-1-one is particularly preferred.
Moreover, the β-glucuronidase inhibitors described above may be used in combination of two or more.

[Surfactant]
The composition for suppressing urine odor production according to the present invention comprises a β-glucuronidase inhibitor and an alkylglycoside-type nonionic surfactant in combination with β for the intracellular β-glucuronidase of microorganisms involved in urine odor production. -Improve glucuronidase inhibitory effect. This effect can be obtained regardless of the presence or absence of the bactericidal effect due to the alkylglycoside type nonionic surfactant. Although the detailed mechanism of the inhibitory effect improvement is unknown, the surfactant acts on the microbial cell membrane to promote the penetration of β-glucuronidase inhibitor into the microbial cell, or the cell membrane structure itself Has an effect of improving the effect of a β-glucuronidase inhibitor on intracellular β-glucuronidase by exposing the intracellular β-glucuronidase to the outside by destroying or by some action other than the above or a plurality of actions including these I guess it.

  Examples of the alkylglycoside nonionic surfactant used in the present invention include those represented by the following general formula (Surf-1).

R ¹ − (OR ² ) _a G _b (Surf-1)

[Wherein R ¹ represents an alkyl group having 8 to 16, preferably 8 to 14, more preferably 8 to 12, and particularly preferably 10 to 12 carbon atoms, and R ² represents an alkylene group having 2 to 4 carbon atoms. Preferably ethylene group or propylene group, particularly preferably ethylene group. G represents a residue derived from a reducing sugar, preferably a glucose residue or a galactose residue, and more preferably a glucose residue. a is a number of 0 to 6, particularly preferably 0 to 1, which represents the average number of added moles of the oxyalkylene group, and a R ^{2 s} may be the same or different. b is a number of 1 to 10, preferably 1 to 5, particularly preferably 1 or 2, indicating the average degree of condensation of the reducing sugar. ]

  In addition to the above alkylglycoside type nonionic surfactant, other surfactants may be used in combination with the composition for suppressing urine odor production of the present invention. Examples of surfactants that can be used in combination include nonionic surfactants other than alkylglycoside type nonionic surfactants, amphoteric surfactants, cationic surfactants, and anionic surfactants. Amphoteric surfactants and cationic surfactants are preferred, and cationic surfactants are particularly preferred. Hereinafter, the surfactant that can be used in combination with the alkyl glycoside type nonionic surfactant of the present invention will be described in detail.

Other nonionic surfactants Nonionic surfactants include polyoxyalkylene alkyl ether type nonionic surfactants represented by the following general formula (Surf-2), and represented by the following general formula (Surf-3) Mention may be made of amine oxide type nonionic surfactants.

R ³ − (OR ⁴ ) _c —OH (Surf-2)

[Wherein R ³ represents a hydrocarbon group having 8 to 16 carbon atoms, preferably 10 to 14 carbon atoms, preferably an alkyl group, and R ⁴ represents an alkylene group having 2 or 3 carbon atoms, preferably an ethylene group. And c is a number of 3 to 20 indicating the average number of moles added of the oxyalkylene group, and the c R ⁴ groups may be the same or different. ]

[In the formula, R ⁵ represents a linear alkyl group having 8 to 16, preferably 16 to 16, particularly preferably 10 to 14 carbon atoms, R ⁶ represents an alkylene group having 2 to 4 carbon atoms, preferably ethylene. A group or a propylene group, X represents —COO— or —CONH—, d represents a number of 0 or 1, and R ⁷ and R ⁸ each independently represents an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. And preferably a methyl group. ]

-Amphoteric surfactants As amphoteric surfactants, sulfobetaine-type amphoteric surfactants and carbobetaine-type amphoteric surfactants are preferred, and specifically, compounds represented by the following general formula (Surf-4) are preferred. .

[Wherein R ⁹ represents a linear alkyl group having 8 to 16 carbon atoms, preferably 10 to 16 carbon atoms, particularly preferably 10 to 14 carbon atoms, and R ¹⁰ represents an alkylene group having 2 to 4 carbon atoms, preferably ethylene. A group or a propylene group, Y represents —COO— or —CONH—, e represents a number of 0 or 1, and R ¹¹ and R ¹² each independently represents an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. And preferably a methyl group, and R ¹³ represents an alkylene group having 1 to 3 carbon atoms which may be substituted with a hydroxy group. Z ⁻ represents —SO ₃ ^— or —COO ^— . ]

-Cationic surfactant As the cationic surfactant, one or two of the four groups bonded to the quaternary nitrogen atom is an alkyl group having 8 to 12 carbon atoms, and the remaining is an alkyl group having 1 to 3 carbon atoms. A quaternary ammonium salt type surfactant which is a group, a hydroxyalkyl group or a benzyl group is preferred. Many of these quaternary ammonium salt type surfactants have antibacterial activity. As such, a dialkyl (preferably both having 10 carbon atoms) dimethylammonium salt or a monoalkyl (preferably 12 carbon atoms) benzyldimethylammonium salt is preferred, and a dialkyl (preferably both having 10 carbon atoms) dimethylammonium salt is more preferred. preferable.

Anionic surfactants Anionic surfactants include alkylbenzene sulfonates, polyoxyalkylene alkyl ether sulfates, alkyl sulfates, α-olefin sulfonates having an alkyl or alkenyl group having 10 to 18 carbon atoms. , Α-sulfo fatty acid salts, α-sulfo fatty acid lower alkyl ester salts, and fatty acid salts.

[Composition for suppressing urine odor production]
The composition for suppressing urine odor production of the present invention comprises a β-glucuronidase inhibitor and 0.01 to 10% by weight of an alkyl glycoside surfactant.

  The content of the β-glucuronidase inhibitor in the composition for suppressing urine odor production of the present invention is preferably 0.001 to 10% by weight, more preferably 0.005 to 1% by weight, and further 0.01 to 0.5% by weight. Is preferable. In addition, the composition for suppressing urine odor production of the present invention is preferably used so that the concentration of the β-glucuronidase inhibitor is 0.0005 to 5% by weight, more preferably 0.0025 to 0.5% by weight in a mixed state with urine components. Furthermore, it is preferable to use it so that it may become 0.005-0.25weight%.

The content of the alkylglycoside type nonionic surfactant in the composition for suppressing urine odor production of the present invention improves the inhibitory effect on intracellular β-glucuronidase and the urine odor production inhibitory effect, and has a good feel. In view of the above, it is 0.01 to 10% by weight, and preferably 0.05 to 2.5% by weight. Further, when other surfactants are used in combination with the alkylglycoside type nonionic surfactant, the total content of the surfactant in the composition for suppressing urine odor production of the present invention is preferably 0.01 to 10% by weight. Furthermore, 0.1 to 5% by weight is preferable.
The weight ratio of the alkylglycoside type nonionic surfactant and β-glucuronidase inhibitor is preferably 500: 1 to 1:10, more preferably 50: 1 to 1: 5, and particularly preferably 10: 1 to 1: 2.

(Other)
The composition for suppressing urine odor production of the present invention further includes, for example, antibacterial agents, chelating agents, deodorant bases, organic solvents, oils, alcohols, pH adjusters, bactericides, preservatives, thickeners, dyes. Ingredients such as flavors, fragrances, moisturizers, softeners, keratin protective agents, medicinal agents, antioxidants, metal salts and metal ions are arbitrarily blended to the extent that they do not impair the effects of the present invention. be able to.

Antibacterial agent As the antibacterial agent, in addition to the cationic surfactant which is one of the surfactants used in the present invention, a cloth in which 1% by weight of the compound is uniformly attached to a cotton gold width # 2003 is used. JIS L 1902 An antibacterial test can be performed by the method of “Fiber product antibacterial test method”, and a compound having a blocking band can be used. Such compounds are described in pages 501 to 564 of “Science of cosmetics, pharmaceutical preservatives and fungicides” (by Koichi Yoshimura and Hirofumi Takikawa, published by Fragrance Journal, April 10, 1990). You can choose from.

  Preferred antibacterial compounds include 2- (4-thiocyanomethylthio) benzimidazole, polylysine, polyhexamethylene biguanide and chlorhexidine glucuronate, triclosan, bis- (2-pyridylthio-1-oxide) zinc, 2,4,5 1,6-tetrachloroisophthalonitrile, trichlorocarbanilide, 8-oxyquinoline, dehydroacetic acid, benzoates, chlorocresols, chlorothymol, chlorophene, dichlorophen, bromochlorophene, hexachlorophene 1 More than one species can be mentioned, and triclosan is particularly preferred from the viewpoint of antibacterial effect. Triclosans described in JP-A-11-189975 are also good, and specifically, dichlorohydroxydiphenyl ether and monochlorohydroxydiphenyl ether are preferable. In addition, inorganic antibacterial agents containing silver, zinc and the like other than those described above can also be used. These antibacterial agents may be used alone or in combination of two or more.

Chelating agent When the composition for suppressing urine odor production according to the present invention is used for a toilet, the chelating agent removes an inorganic substance such as calcium phosphate adhering to the toilet by the chelating agent, thereby Since the production | generation suppression effect can be improved, it can use suitably.

Examples of the chelating agent include the following compounds.
(1) Phosphate compounds such as phytic acid, or alkali metal salts or alkanolamine salts thereof;
(2) Ethane-1,1-diphosphonic acid, ethane-1,1,2-triphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid, ethanehydroxy-1,1,2-triphosphonic acid, ethane- Phosphonic acids such as 1,2-dicarboxy-1,2-diphosphonic acid, methanehydroxyphosphonic acid, or alkali metal salts or alkanolamine salts thereof;
(3) Phosphonocarboxylic acids such as 2-phosphonobutane-1,2-dicarboxylic acid, 1-phosphonobutane-2,3,4-tricarboxylic acid, α-methylphosphonosuccinic acid, or alkali metal salts or alkanolamines thereof salt;
(4) amino acids such as aspartic acid, glutamic acid and glycine, or alkali metal salts or alkanolamine salts thereof;
(5) Nitrilotriacetic acid, iminodiacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, glycol etherdiaminetetraacetic acid, hydroxyethyliminodiacetic acid, triethylenetetraminehexaacetic acid, diencoric acid, alkyl (1 to 3 carbon atoms) glycine- Aminopolyacetic acid such as N, N-diacetic acid, aspartic acid-N, N-diacetic acid, serine-N, N-diacetic acid, glutamic acid diacetic acid, ethylenediamine succinic acid, or a salt thereof, preferably an alkali metal salt, or Alkanolamine salts;
(6) Organic acids such as diglycolic acid, oxydisuccinic acid, carboxymethyloxysuccinic acid, citric acid, lactic acid, tartaric acid, oxalic acid, malic acid, oxydisuccinic acid, gluconic acid, carboxymethylsuccinic acid, carboxymethyltartaric acid, or these Alkali metal salts or alkanolamine salts of
(7) Aminopoly (methylenephosphonic acid) or an alkali metal salt or alkanolamine salt thereof, or polyethylenepolyaminepoly (methylenephosphonic acid) or an alkali metal salt or alkanolamine salt thereof.

  Among these, at least one selected from the group consisting of (2), (5) and (6) is preferable, and at least one selected from the group consisting of (5) and (6) is more preferable. The most preferred components are ethylenediaminetetraacetic acid, methylglycine-N, N-diacetic acid and citric acid. These chelating agents may be used alone or in combination of two or more.

・ Deodorant base Examples of deodorant base include
Metal compounds such as iron oxide, iron sulfate, iron chloride, zinc oxide, zinc sulfate, zinc chloride, silver oxide, copper oxide;
Acids such as phosphoric acid, citric acid and succinic acid, and triethanolamine, monoethanolamine, sodium hydroxide, potassium hydroxide, 2-amino-2-hydroxymethyl-1,3-propanediol (tris (hydroxymethyl) An acid or a salt thereof having a pH buffering effect comprising a combination with a base such as aminomethane);
Carboxylic acids such as lactic acid, succinic acid, malic acid, citric acid, maleic acid, malonic acid;
Fatty acid metals such as zinc undecylenate, zinc 2-ethylhexanoate, zinc ricinol;
Plant extract-type deodorants such as catechin, polyphenol, green tea extract, mushroom extract, wood vinegar and bamboo vinegar
Metal type chlorophyllin sodium such as iron and copper, metal phthalocyanine such as iron, copper and cobalt, catalyst type such as tetraphthalic acid phthalocyanine such as iron, copper and cobalt, titanium dioxide, visible light responsive titanium dioxide (nitrogen doped type, etc.) Deodorants;
cyclodextrins such as α-, β-, or γ-cyclodextrin, its methyl derivatives, hydroxypropyl derivatives, glucosyl derivatives, maltosyl derivatives;
Alkylene glycols that are said to have a retention of malodor such as ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol;
Ester oil agent that is said to have an effect of retaining bad odor such as myristic acid esters, palmitic acid esters, phthalic acid esters, adipic acid esters, sebacic acid esters, citrate esters;
Acrylic acid polymer such as porous methacrylic acid polymer and porous acrylic acid polymer, porous divinylbenzene polymer, porous styrene-divinylbenzene-vinylpyridine polymer, aromatic polymer such as porous divinylbenzene-vinylpyridine polymer, and copolymers thereof Synthetic porous polymers such as chitin, chitosan and other natural porous polymers;
Inorganic porous materials such as activated carbon, silica, silicon dioxide (silica gel), calcium silicate, high silica zeolite (hydrophobic zeolite), sepiolite, cancrinite, zeolite, hydrated zirconium oxide;
Examples thereof include metal-supporting porous materials such as silver-supporting zeolite, silver-supporting cancrinite, and silver-supporting porous styrene-divinylbenzene-vinylpyridine polymer. These deodorant bases may be used alone or in combination of two or more.

Organic solvent As the organic solvent, a water-soluble organic solvent is preferable, for example,
Alcohols such as ethanol, 1-propanol, 2-propanol, butyl alcohol;
Ethylene glycol, 1,2-propanediol, 1,3-butanediol, hexylene glycol, 2-ethyl-1,3-hexanediol, glycerin, triethylene glycol, dipropylene glycol, diglycerin, polyethylene glycol, polypropylene glycol Polyhydric alcohols such as
And ethers such as ethylene glycol ethyl ether, ethylene glycol methyl ether, ethylene glycol butyl ether, and diethylene glycol ethyl ether. These organic solvents may be used alone or in combination of two or more.

[Urine odor production suppression method, product form]
By containing an effective amount of the composition for suppressing urine odor production of the present invention in products for household use and facilities, or using it as it is, it exhibits a high inhibitory effect and deodorizing effect on the production of malodor derived from urine. be able to. In addition, the composition for suppressing urine odor production according to the present invention is applied to an object (an object for which generation of urine odor is to be suppressed) before urine adheres or after the urine adhering to the urine is dried. The production of urine odor can be effectively suppressed by applying within 1 hour, more preferably within 10 minutes, preferably after urine adheres.

  The urine is not limited to those derived from humans, and may be urine derived from animals such as pets such as dogs and cats. The malodor derived from urine is not limited to the malodor generated from urine alone, and may be a malodor generated from a state in which urine and feces are mixed in a diaper, for example.

  The malodorous components that can be controlled by the composition for suppressing urine odor production of the present invention are phenolic compounds and indoles, specifically phenol, p-cresol, 4-vinyl-2-methoxy-phenol, 4-vinyl. Examples include phenol, 2-methoxy-1,3-benzenediol, 1,4-benzenediol, 1,3-benzenediol, and indole, but are not limited to this, and β-glucuronidase acts on urine. Any volatile component may be generated.

(Product form)
As a product form, a product to which the composition for suppressing urine odor production of the present invention is applied directly to an object such as a discharge-type product, a coated product, a wiping product, or the urine of the present invention at a portion where urine is collected. An absorptive product that holds the composition for suppressing odor generation can be mentioned.

The discharge type product is a container having a trigger sprayer, a button type spray container, an aerosol container, a squeeze container or the like, a container having a discharge device for discharging in a mist or foam form, or a container for a drop type product. It is a product that contains a composition for suppressing odor generation and is applied to an object by a discharge device. Among these, a product using a trigger type or button type spray discharge device is preferable. The discharge-type product by dripping includes a product installed on a toilet tank or in a toilet bowl and applied by flowing into the toilet toilet bowl.
In the case of a discharge-type product, the water content in the composition for suppressing urine odor production is preferably 50 to 99% by weight, more preferably 70 to 98% by weight, and still more preferably 80 to 95% by weight. . Moreover, the pH at 20 ° C. of the composition for suppressing urine odor production contained in the discharge-type product is preferably 5 to 9, more preferably 6 to 8, and pH adjustment is performed with a commonly used pH adjuster. .

  A coated product or a wiped product is a product that is applied to an object by impregnating or holding the composition for suppressing urine odor production of the present invention on a holding member such as a porous member or sheet material, and impregnating the sheet material. Sheet products are preferred.

  The absorbent product impregnates or holds the composition for suppressing urine odor production of the present invention in an article in which excrement such as urine is directly absorbed, thereby suppressing urine odor production by the absorbed urine. In the absorbent product, the composition for suppressing urine odor production of the present invention does not directly touch human skin, but is preferably capable of coming into contact with absorbed urine, for example, an intermediate layer of a sheet product having a multilayer structure. The water-absorbing polymer, pulp, non-woven fabric and / or backing paper used in the present invention are impregnated or retained with the composition for suppressing urine odor production of the present invention. Among these, a water-absorbing polymer and / or pulp impregnated or retained with the composition for suppressing urine odor production of the present invention is more preferable, and a water-absorbing polymer impregnated or retained is particularly preferable.

  In the following Reference Examples and Examples, a 0.2 μm filter (a filter unit manufactured by Millipore, Milex GV, or Nalgen) was used as a filter for sterilization. Unless otherwise specified, β-glucuronidase Type VII-A (purchased from Sigma) derived from E. coli was used as β-glucuronidase. In addition, an absorbance microplate reader (TECAN, Sunrise Rainbow Thermo RC) was used for absorbance measurement, and the absorbance of the sample at each wavelength was measured in a well of a 96-well microwell plate (NUNC, Nunclon Delta Surface). Measurements for 200 μL of sample were used.

Reference Example 1 Production of volatile compounds from urine by addition of β-glucuronidase
(1) Preparation of measurement sample In a γ-ray sterilized container, immediately after collection, 9.9 mL of a human urine sample (mixture of 5 human urine) that was sterilized with a 0.2 μm filter was placed, followed by 250 units. β-glucuronidase Type VII-A aqueous solution adjusted to 0.1 mL / mL was added and mixed, and the mixture was allowed to stand in a thermostatic bath at 25 ° C. and reacted for 22 hours. What added 0.1 mL of sterilized ion-exchange water instead of the enzyme solution was similarly left as an initial urine sample in a thermostat for 22 hours.
After completion of the reaction, benzyl benzoate ethanol solution was added as an internal standard to 9 mL of the reaction solution, and extracted twice with 10 mL of diethyl ether. The extracts were combined and dried over anhydrous magnesium sulfate. After drying, the solid matter was filtered off, and the filtrate was concentrated with a rotary evaporator to obtain a measurement sample.

(2) Measurement of volatile compounds A gas chromatograph mass spectrometer was used for measurement. The production amount of the detected volatile compound was calculated as a peak area ratio with respect to the internal standard. The results are shown in Table 1.

  From these results, it was confirmed that various phenolic compounds and indole were produced from urine by the action of β-glucuronidase.

Reference Example 2 Inhibition of β-glucuronidase activity by specific compounds and plant extracts 100 μL of 2 mM PNPG aqueous solution, 40 μL of 0.5 M phosphate buffer (pH 6.8), 38 μL of ion exchange water, various compounds or 2 μL of 10 or 1 wt% dipropylene glycol (DPG) solution of plant extract was mixed, followed by addition of 20 μL of β-glucuronidase aqueous solution adjusted to 16 units / mL, and the enzyme reaction was performed in a 37 ° C. constant temperature bath for 2 hours. . For some compounds, the same experiment was conducted for a 0.1 wt% DPG solution. The concentrations of the supplied compound and plant extract in the reaction solution are 0.1, 0.01, and 0.001% by weight, respectively. In addition, the reaction was performed in the same manner for 2 hours using the above compound and plant extract with DPG added as a control, and each sample and control with ion exchange water added in place of the enzyme solution as a blank. It was.
The reaction solution was diluted with 0.2 M glycine-sodium hydroxide buffer (pH 10.4), and the absorbance at a wavelength of 400 nm was measured. From the obtained measured values, the relative activity inhibition rate of β-glucuronidase was determined according to the following formula, and is shown in Table 2a and Table 2b.

  From this result, it can be seen that the provided compound and plant extract sample have β-glucuronidase inhibitory activity.

Reference Example 3 Suppression of urine-derived volatile compounds by β-glucuronidase inhibitors
(1) Preparation of sample 9.9 mL of human urine sample (mixture of 5 human urine), 10% by weight 8- 10 μL of cyclohexadecen-1-one DPG solution was added, and then 0.1 mL of a β-glucuronidase aqueous solution adjusted to 250 units / mL was added and mixed, and the mixture was allowed to stand in a 25 ° C. constant temperature bath and reacted for 22 hours. The concentration of 8-cyclohexadecen-1-one in the reaction solution is 0.01% by weight. In addition, each of 9.9 mL of sterilized urine sample was added with 0.1 mL of enzyme solution as a control, and 9.9 mL of sterilized urine sample added with 0.1 mL of ion-exchanged water was used as a blank, and reacted for 22 hours.
After completion of the reaction, benzyl benzoate ethanol solution was added as an internal standard to 9 mL of the reaction solution, and extracted twice with 10 mL of diethyl ether. The extracts were combined and dried over anhydrous magnesium sulfate. After drying, the solid matter was filtered off, and the filtrate was concentrated with a rotary evaporator to obtain a measurement sample.

(2) Inhibition of volatile compound formation A gas chromatograph mass spectrometer was used for measurement. The production amount of the detected volatile compound was calculated as a peak area ratio with respect to the internal standard. From the obtained value, the production inhibition rate for each volatile component was determined according to the following formula and shown in Table 3.

  From this result, it can be seen that the β-glucuronidase inhibitor (8-cyclohexadecen-1-one) suppressed the production of all phenolic compounds and indoles produced from urine by the action of β-glucuronidase.

Examples 1-1 to 1-4, Comparative Examples 1-1 to 1-3 Improvement of inhibitory effect by combined use of β-glucuronidase inhibitor and surfactant (1) Collection of urine odor producing bacteria Three panelists' homes Β-glucuronidase using SCDLP agar plate medium (manufactured by Nippon Pharmaceutical Co., Ltd.) supplemented with β-glucuronidase activity detection reagent (5-bromo-4-chloro-3-indolyl-β-D-glucuronide) from the back of toilet toilet Active bacteria were collected and separated. Occurrence of odor was confirmed when these strains were cultured in sterilized urine. Among them, a strain that generated particularly strong odor was used as a urine odor producing bacterium in this example. This strain was confirmed to be attributed to E. coli by 16S rDNA partial nucleotide sequence analysis.

(2) Preparation of Bacterial Solution The above urine odor producing bacteria were cultured in Mueller Hinton medium containing 3 mM PNPG, and the liquid part was removed by centrifugation. The remaining bacterial cell part was suspended in physiological saline, the liquid part was removed again by centrifugation, and this operation was performed twice to wash the bacterial cell part. This was appropriately diluted with D-PBS (Dulbecco's Phosphate Buffered Saline) and adjusted so that the absorbance at a wavelength of 600 nm was 0.4.

(3) Inhibitory effect measurement of β-glucuronidase activity in urine odor producing bacteria Into 200 μL of 200 mM phosphate buffer (pH 6.8) containing 2 mM PNPG, alkylglycoside type nonion as Examples 1-1 to 1-4 40 μL of a surfactant, a polyoxyethylene sorbitan fatty acid ester type nonionic surfactant as Comparative Example 1-1, and each 1 w / v% aqueous solution of a water-soluble organic solvent as Comparative Examples 1-2 and 1-3 were added and mixed. 4 μL of 1 w / v% β-glucuronidase inhibitor (8-cyclohexadecen-1-one) ethanol solution was added and mixed, and ion-exchanged water was further added to make 380 μL. Further, as Comparative Example 1-4 (inhibitor only), 200 μL of 200 mM phosphate buffer (pH 6.8) containing 2 mM PNPG was added and mixed with 4 μL of 1 w / v% β-glucuronidase inhibitor ethanol solution, and further ionized. A solution was prepared by adding exchange water to 380 μL.
20 μL of the urine odor producing bacterial solution prepared in this Example (2) was added to and mixed with these solutions and reacted in a 37 ° C. constant temperature bath for 1 hour. The concentrations in the reaction solution are 0.01 w / v% for the β-glucuronidase inhibitor, 0.1 w / v% for the surfactant and the water-soluble organic solvent, or “none” (Comparative Example 1-4). In addition, the composition of Comparative Example 1-4 was reacted in the same manner using as a control a mixture obtained by adding ethanol instead of the inhibitor solution. Furthermore, the control composition was changed to D-PBS and the same operation was performed to obtain a blank.
After completion of the reaction, a part of the reaction solution is diluted with 0.2 M glycine-sodium hydroxide buffer (pH 10.4), centrifuged at 10,000 rpm for 2 minutes, and the centrifuged supernatant is used at a wavelength of 400 nm. Absorbance was measured. From the obtained measured values, the relative activity of β-glucuronidase in urine odor producing bacteria in each sample was determined according to the following formula, and the results are shown in Table 4.

  In addition, for alkylglycoside type nonionic surfactants, in order to evaluate even lower concentrations, the same measurement was performed with the addition amount of 1 w / v% aqueous solution being 1/20 (2 μL), and the results are shown. This is shown in FIG. At this time, the concentrations in the reaction solution are 0.01 w / v% for the β-glucuronidase inhibitor and 0.005 w / v% for the active agent, respectively.

<Additive components>
Dodecyl glucoside: manufactured by Kao Corporation, using Mydol 12 Decyl glucoside: manufactured by Kao Corporation, using Mydol 10 Isodecyl galactoside: synthesized according to the method described in JP 2008-156271 A Octyl Galactoside: Use the one synthesized according to the method described in JP-A-2008-156271 Polyoxyethylene sorbitan monooleate: Kao Co., Ltd., using Rhedol Super TW-O120 Glycerol: Katayama Chemical Co., Ltd. Use the purchased propylene glycol: Use the one purchased from Asahi Glass Co., Ltd.

  As shown in the above results, the alkylglycoside type nonionic surfactant improved the inhibitory effect when used in combination with the β-glucuronidase inhibitor. In particular, the alkyl glucosides listed in Examples 1-1 and 1-2 exhibited a good inhibitory effect even when the addition amount was 1/20 (0.005 w / v%). Such an effect could not be obtained by adding other nonionic surfactants such as polyoxyethylene sorbitan monooleate and general water-soluble organic solvents. In other words, the improvement in enzyme activity inhibition effect is a unique effect due to the combined use of alkylglycoside type nonionic surfactants. Simply improving the solubilization ability of β-glucuronidase inhibitor in aqueous solution will inhibit the enzyme activity. Did not improve.

Reference Example 4 Increasing cell penetration / attachment amount of β-glucuronidase inhibitor by surfactant (1) Preparation of bacterial solution Examples 1-1 to 1-4 and Comparative Examples 1-1 to 1-3 (1 The urine odor producing bacteria obtained in (1) were cultured in Mueller Hinton medium, and the liquid part was removed by centrifugation. The remaining bacterial cell part was suspended in physiological saline, the liquid part was removed again by centrifugation, and this operation was performed twice to wash the bacterial cell part. This was appropriately diluted with D-PBS (Dulbecco's Phosphate Buffered Saline) and prepared so that the absorbance at a wavelength of 600 nm was 8.

(2) Measurement of cell penetration / attachment amount of β-glucuronidase inhibitor 0.01 w / v% of β-glucuronidase inhibitor (8-cyclohexadecen-1-one) in D-PBS according to the formulation shown in Table 5 The dodecyl glucoside used in Example 1-1 was 0, 0.01, or 0.1 w / v%, or the polyoxyethylene sorbitan monooleate used in Comparative Example 1-1 was 0.1 w / v%, and the cells were at a wavelength of 600 nm. Each solution was prepared so that the absorbance in the reaction solution was 0.4 or 0.8.
This solution was allowed to stand in a 37 ° C. constant temperature bath for 2 hours, and then the bacterial cell part was recovered by centrifugation and washed several times with an aqueous sodium chloride solution. Subsequently, a small amount of physiological saline was added to resuspend the contents, transferred to a glass container, sealed, and subjected to ultrasonic treatment to crush the cells. After adding a benzyl benzoate ethanol solution as an internal standard, the inhibitor was extracted with diethyl ether. The extract was dried over anhydrous magnesium sulfate, the solid matter was filtered off, and the filtrate was concentrated to obtain a measurement sample.
A gas chromatograph mass spectrometer was used for the measurement, and the detected amount of inhibitor from the cells was calculated as the peak area ratio relative to the internal standard. The results are shown in FIG.

  From the above results, it can be seen that the alkylglycoside type nonionic surfactant promotes the penetration or adsorption of the β-glucuronidase inhibitor into the cells.

Examples 2-1 and 2-2, Comparative Examples 2-1 and 2-4 Improvement of inhibitory effect and suppression of urine odor production by combined use of β-glucuronidase inhibitor and surfactant (1) Preparation of bacterial solution The urine odor producing bacteria obtained in (1-1) of Examples 1-1 to 1-4 and Comparative Examples 1-1 to 1-3 were cultured in human urine samples (sterilized, mixture of two equivalents), The liquid part was removed by centrifugation. The remaining bacterial cell part was suspended in physiological saline, the liquid part was removed again by centrifugation, and this operation was performed twice to wash the bacterial cell part. This was appropriately diluted with physiological saline and prepared so that the absorbance at a wavelength of 600 nm was 2.

(2) Measurement of inhibitory effect on intracellular β-glucuronidase activity of urine odor producing bacteria β-glucuronidase inhibitor (8-cyclohexadecen-1-one) having the composition (w / v%) shown in Table 6 and / or of the present invention For inhibiting urine odor production in Examples 2-1 and 2-2 and Comparative Examples 2-1 to 2-4 containing an alkylglycoside type nonionic surfactant (dodecylglucoside: manufactured by Kao Corporation, Mydol 12) Compositions were prepared, and each composition and human urine sample (sterilized, mixture of two equivalents) were mixed at a volume ratio of 1: 4. PNPG is dissolved so that it becomes 1 mM with respect to urine added with these compositions, and further, 1 vol% of the urine odor producing bacterial solution prepared in this Example (1) is added and mixed. The reaction was allowed to proceed for 4 hours in the bath. The concentration in the reaction solution is 0.01 w / v% for the β-glucuronidase inhibitor and 0.005 w / v% or 0.1 w / v% for the surfactant, respectively.
In addition, each sample was similarly reacted for 4 hours using a blank obtained by adding physiological saline instead of the bacterial solution.
After completion of the reaction, a part of the reaction solution is diluted with 0.2 M glycine-sodium hydroxide buffer (pH 10.4), centrifuged at 10,000 rpm for 2 minutes, and the centrifuged supernatant is used at a wavelength of 400 nm. Absorbance was measured. From the obtained measured values, the relative activity of β-glucuronidase in urine odor producing bacteria in each sample was determined according to the following formula, and the results are shown in Table 6.

(4) Antibacterial effect measurement About each sample shown in Table 6, after reacting at 30 ° C for 4 hours, a part of it was diluted with LP diluent (manufactured by Nippon Pharmaceutical Co., Ltd.) and inoculated on SCDLP agar plate medium. Then, the number of viable bacteria was measured. A sample having the same composition as Comparative Example 2-4 was prepared separately, and immediately after the addition of the bacterial solution, the number of viable bacteria was measured by the same method, and this was used as the initial number of added bacteria. Measurement was performed three times for the same sample, and the average value of the sample was less than 1/10 of the initial number of bacteria added. The product was determined to have no antibacterial effect (denoted as x), and the results are shown in Table 6.

(5) Odor strength evaluation (measurement of odor generation suppression effect)
About each sample shown in Table 6, what was made to react at 30 degreeC for 4 hours was dripped at the odor paper tip equally, and this was made into the odor evaluation sample. Odor intensity evaluation was conducted in accordance with a 6-step odor intensity display method based on an evaluation score of 0 to 5 by two professional panelists who have qualifications as an odor judge. That is, the evaluation score is “0” odorless, “1” is finally perceivable odor (detection threshold), “2” urine odor is known, but weak odor (cognitive threshold), “3” feels urine odor easily. Odor, “4” strong urine odor, “5” intense urine odor. The odor intensity was determined in increments of 0.5, and the average value of the evaluation of the two persons was set to 0.5 when the numerical value after the decimal point was 0.25 or more and less than 0.75, rounded up to 0.75 or more and rounded down to less than 0.25. The results obtained are shown in Table 6.

  As shown in the above results, the surfactant alone cannot suppress the activity of β-glucuronidase derived from urine odor producing bacteria regardless of the antibacterial effect, and the urine odor production suppressing effect is not obtained. It was. On the other hand, the composition for suppressing urine odor production comprising the β-glucuronidase inhibitor and the alkylglycoside type nonionic surfactant of the present invention is more effective than the case where the β-glucuronidase inhibitor is used alone regardless of the antibacterial effect. It showed excellent inhibitory activity against intracellular β-glucuronidase, and more effectively suppressed urine odor production.

Example 3 Spray-type product A composition for suppressing urine odor production containing a β-glucuronidase inhibitor (8-cyclohexadecen-1-one) having a composition (% by weight) shown in Table 7 and various surfactants was prepared. This was put into a trigger spray container to produce a spray-type product. The pH of the composition was adjusted to 6.5-7.5.

<Compounding ingredients (surfactant)>
Alkyl glycoside type nonionic surfactant 1: dodecyl glucoside (manufactured by Kao Corporation, Mydol 12, average degree of condensation of glucose 1.3)
Alkyl glycoside type nonionic surfactant 2: Decyl glucoside (manufactured by Kao Corporation, Mydol 10)
Alkyl glycoside type nonionic surfactant 3: Isodecyl galactoside Alkyl glycoside type nonionic surfactant 4: Octyl galactoside Nonionic surfactant 1: N-lauroylaminopropyl-N, N-dimethylamine oxide Nonionic surfactant 2: Polyoxyethylene (average 8 mol) lauryl ether Amphoteric surfactant 1: N-lauroylaminopropyl-N, N-dimethyl-N- (2-hydroxysulfopropyl) ammonium betaine Amphoteric surfactant 2: N-lauroyl Aminopropyl-N, N-dimethyl-N-carboxymethylammonium betaine Cationic surfactant 1: Didecyldimethylammonium chloride (manufactured by Kao Corporation, Coatamine D-10E)
Cationic surfactant 2: Alkylbenzylammonium chloride (manufactured by Kao Corporation, Sanizol C, carbon number of alkyl group is 12)
Anionic surfactant 1: Sodium alkylbenzene sulfonate (the alkyl group has 11 to 15 carbon atoms)
Anionic surfactant 2: Sodium lauryl sulfate

Claims (8)

  A composition for suppressing urine odor production, comprising a β-glucuronidase inhibitor and 0.01 to 10% by weight of an alkylglycoside type nonionic surfactant. The composition for suppressing urine odor production according to claim 1, comprising at least a macrocyclic compound represented by any one of the general formulas (1) to (3) as a β-glucuronidase inhibitor.

Wherein, n ₁ represents an integer of 9 to 13, m ₁ represents an integer of 0 to 2, may contain one double bond broken line. ]

Wherein, n ₂ represents an integer of 9 to 13, m ₂ represents an integer of 0 to 3, including one double bond broken line. However, it is assumed that satisfies n ₂ + m ₂ = 9~14. ]

[In formula, R shows a hydrogen atom or a C1-C3 alkyl group, p shows the integer of 6-11, q shows the integer of 2-6. However, p + q = 10-14 shall be satisfy | filled. ]   The composition for suppressing urine odor production according to claim 2, comprising at least a macrocyclic ketone represented by the general formula (1) as a β-glucuronidase inhibitor.   The composition for suppressing urine odor production according to any one of claims 1 to 3, wherein the alkyl group of the alkylglycoside type nonionic surfactant has 8 to 12 carbon atoms.   The composition for suppressing urine odor production according to any one of claims 1 to 4, wherein the residue derived from the reducing sugar of the alkylglycoside type nonionic surfactant is selected from a glucose residue and a galactose residue.   A discharge-type product comprising the composition for suppressing urine odor production according to any one of claims 1 to 5 contained in a container provided with a discharge device.   A method for suppressing urine odor production, wherein the composition for suppressing urine odor production according to any one of claims 1 to 5 is applied before urine adheres to an object or before drying after urine adheres.   The method for suppressing the generation of urine odor according to claim 7, wherein the application of the composition for suppressing urine odor generation to an object is discharge from a container provided with a discharge device or adhesion to the object by application.

Images